IP Library Granted Patent US 8,551,782
Granted Patent B2
US 8,551,782 · App. 13/431,534 · Granted Oct 8, 2013

Methods for promoting HSC engraftment

Inventors: Leonard I. Zon (Wellesley, MA); Trista E. North (Newton Center, MA); Wolfram Goessling (Chestnut Hill, MA)
Assignees: Children's Medical Center Corporation; The General Hospital Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,551,782
App. No.
13/431,534
Granted
Oct 8, 2013
Kind
B2
Abstract

The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E 2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.

Claims (11)

1. A method for promoting hematopoietic stem cell (HSC) engraftment in a human subject in need thereof, comprising

contacting a population of human HSCs ex vivo with an effective amount of 16,16-dimethyl-PGE 2 to promote engraftment of the HSC in the subject; and

administering the contacted HSCs to the subject, wherein the population of human HSCs is autologous or allogeneic to the subject.

2. The method of claim 1 , wherein the population of human HSCs is obtained from peripheral blood, cord blood, bone marrow, amniotic fluid, or placental blood.

3. The method of claim 1 , wherein the population of human HSCs is obtained from peripheral blood or cord blood.

4. The method of claim 1 , wherein the subject is a candidate for bone marrow or stem cell transplantation, or a subject that has received bone marrow ablating chemotherapy or irradiation therapy.

5. The method of claim 1 , wherein the subject has a solid tumor, myeloma, or lymphoma.

6. The method of claim 1 , wherein the subject has anemia.

7. The method of claim 6 , wherein the anemia is sickle cell anemia, thalassemia, or aplastic anemia.

8. The method of claim 1 , wherein the population of human HSCs is autologous to the subject.

9. The method of claim 1 , wherein the population of human HSCs is allogeneic to the subject.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2016
From: GOESSLING, WOLFRAM
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 039542/0256 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2016
From: NORTH, TRISTA E.; ZON, LEONARD I.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 039542/0268 →
CONFIRMATORY LICENSE Recorded Jun 22, 2015
From: MASSACHUSETTS GENERAL HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035984/0296 →
Continuity (3)
Continuation 12294344
Provisional Application 60785968 · Mar 24, 2006
Related Publication 20120189593A1 · Jul 26, 2012